Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.
| Revenue (TTM) | 15,000 |
| Gross Profit (TTM) | 15,000 |
| EBITDA | $-192.25M |
| Operating Margin | -1609833.00% |
| Return on Equity | -97.80% |
| Return on Assets | -36.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $11.68 |
| Price-to-Book | 1.91 |
| Price-to-Sales (TTM) | 24356.10 |
| EV/Revenue | 15066.17 |
| EV/EBITDA | 0.25 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -80.00% |
| Shares Outstanding | $24.59M |
| Float | $9.85M |
| % Insiders | 28.63% |
| % Institutions | 48.80% |
Volatility is currently expanding
Lyell Immunopharma NASDAQ: LYEL expects pivotal data in mid-2027 for its lead CAR-T cell therapy, ronde-cel, as the company advances the treatment in patients with large B-cell lymphoma who have received at least two prior lines of therapy.
Lyell Immunopharma is upgraded to “Buy” as pivotal ronde-cel CAR-T programs advance in relapsed/refractory large B-cell lymphoma [r/r LBCL]. LYEL secured $80 million in private placement, extending cash runway into 2028 and supporting ongoing pivotal and phase 3 trials. Key catalysts include ASH 2026 data updates for ronde-cel in 2nd/3rd-line r/r LBCL and phase 1/2 data for LYL273 in metastatic colorectal cancer.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financial results and business highlights for the third quarter ended September 30, 2026.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placement of approximately $80 million of its common stock. The investors include ARCH Venture Partners, Adage Capital Management LP, Caligan Partners LP, RTW Investments, a leading mutual fund and other new and existing institutional investors.
Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients with 3L+ R/R LBCL in the PiNACLE pivotal trial Ronde-cel achieved a 95% overall response rate and 76% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 37 patients with 2L R/R LBCL in the Phase 1/2 trial No Grade ≥ 3 cytokine release syndrome was observed in either cohort and Grade ≥ 3 neurotoxicity was reported in < 10% of patients supporting outpatient administration SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that two abstracts featuring positive updated clinical data for rondecabtagene autoleucel (ronde-cel) have been accepted for presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12–15, 2026, in New Orleans (ASH 2026).
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the following investor events: Goldman Sachs' RxChange Series: Framing Lyell's next-generation lymphoma CAR-T data in 4Q Format: Fireside ChatFeatured Speaker: Alexander P.
Lyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026, in New York with a fireside chat scheduled for 2:00 pm Eastern Time.
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced successful completion of the planned technology transfer for LYL273, a guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate, to its LyFE Manufacturing Center™ (LyFE) in Bothell, Washington, following review by the U.S. Food and Drug Administration (FDA). LyFE is implementing an improved manufacturing process and updated analytical methods to enhance manufacturing performance and increase capacity. The Phase 1/2 clinical trial of LYL273 in patients with relapsed/refractory metastatic colorectal cancer (R/R mCRC) continues to enroll patients with the goal of determining the recommended Phase 2 dose and optimized safety management plan. Additional clinical data from the trial and a planned End-of-Phase 1 meeting with the FDA are now expected in 2027.
The average of price targets set by Wall Street analysts indicates a potential upside of 176% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LYEL and any ticker you trade — then tracks every position and per-strategy win rate.
